ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 45

BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program.

Cristina Musselli, Claudia Harper, Linda Burkly, Joan Lane, Chase Chen, Dough Donaldson, Million Arefayene, Karen Smirnakis, Devangi Mehta, Dale Morris and Nathalie Franchimont, Biogen, Cambridge, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Sjogren's syndrome and safety

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

CD40/CD40L is a cornerstone pathway for both innate and adaptive immune responses and a suitable target for autoimmune diseases including Sjogren’s. BIIB063 is a high affinity MAb, engineered to reduce Fc effector function and avoid half antibody formation in vivo (IgG4P). BIIB063 has the potential to inhibit germinal center formation, immunoglobulin class switching, T cell activation and cytokine release with a potent inhibition of inflammation and autoimmunity. The results of the first in human and the GLP-toxicology findings are presented.

Methods:

In the single ascending dose (SAD) study, 58 healthy volunteers (HV) subjects were assigned to 8 cohorts. Seven cohorts of 4, 6, or 8 subjects were planned to receive increasing single IV doses of BIIB063 (0.003, 0.03, 0.3, 1, 3, 10, and 20 mg/kg) or placebo. One cohort of 8 subjects was planned to receive a single 150 mg SC dose of BIIB063 or placebo. Staggered dosing was used within each cohort to ensure subject safety. Blood samples were analyzed by ELISA for PK and ADA, and flow cytometry for the PD measure of CD40 receptor occupancy (RO). Safety data, including adverse events (AEs) and laboratory tests, were collected. A 26-Week SC and IV Toxicity Study in Cynomolgus Monkeys with a 16-Week Recovery Period was conducted; animals received 10, 30 or 150 mg/kg BIIB063 twice monthly.

Results:

In the SAD study, a total of 29 subjects had been enrolled when the study was voluntarily put on hold due to findings from the ongoing 26-week toxicology study where 4 unscheduled terminations occurred. A thorough investigation revealed Immune complex (IgM-IgG4) deposits in multiple organs of affected animals, consistent with a type 3 hypersensitivity. This reaction occurred in 44% animals irrespective of the dose level and no NOAEL could be established. .

In the SAD, BIIB063 serum concentrations for the lowest two doses (0.003–0.03 mg/kg), were below the LLOQ. BIIB063 Cmax and AUCinf ranged from 3.7 to 22 ug/mL and 100 to 1880 hr*ug/mL following doses of 0.3 and 1 mg/kg, respectively. BIIB063 showed nonlinear PKs and a dose-dependent CD40 RO and RO duration. There was no significant RO of CD40 at dose levels of BIIB063 <0.3 mg/kg, while full CD40 RO was observed at doses of 0.3 and 1 mg/kg. CD40 RO declined within 96 hr for the 0.3mg/kg dose while CD40 RO lasted 8 days for the 1 mg/kg dose. BIIB063 was generally well tolerated.

No ADA was observed in the 0.003-0.03 mg/kg cohorts where serum concentrations of drug were undetectable, while 67% – 100% subjects had positive ADA in the 0.3-1 mg/Kg cohorts. Interestingly, ADA responses were typically detected several weeks after BIIB063 drug clearance, and in the absence of CD40RO. Hence, the potential impact of ADA on PK and PD was undeterminable.

Conclusion:

BIIB063 administered to HV exhibited a PK profile consistent with an IgG4 molecule. Target engagement as measured by CD40 RO was clearly demonstrated and its duration was dose dependent. ADA response was present in the higher doses cohorts in the SAD. The preclinical toxicology findings and the high immunogenicity of BIIB063 led to the voluntary discontinuation of the trial.



Disclosure: C. Musselli, Biogen Idec, 1,Biogen Idec, 3; C. Harper, Biogen Idec, 3,Biogen Idec, 1; L. Burkly, Biogen Idec, 3; J. Lane, Biogen Idec, 3,Biogen Idec, 1; C. Chen, Biogen Idec, 3,Biogen Idec, 1; D. Donaldson, Biogen Idec, 1,Biogen Idec, 3; M. Arefayene, Biogen Idec, 1,Biogen Idec, 3; K. Smirnakis, Biogen Idec, 1,Biogen Idec, 3; D. Mehta, Biogen Idec, 1,Biogen Idec, 3; D. Morris, Biogen Idec, 1,Biogen Idec, 3; N. Franchimont, Biogen Idec, 3,Biogen Idec, 1.

To cite this abstract in AMA style:

Musselli C, Harper C, Burkly L, Lane J, Chen C, Donaldson D, Arefayene M, Smirnakis K, Mehta D, Morris D, Franchimont N. BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program. [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/biib063-a-potent-anti-cd40-antagonistic-monoclonal-antibody-mab-lessons-learned-from-an-early-development-program/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biib063-a-potent-anti-cd40-antagonistic-monoclonal-antibody-mab-lessons-learned-from-an-early-development-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology